The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.
Hepatocellular Carcinoma
PROCEDURE: adjuvant transarterial chemoinfusion (TAI)|DRUG: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Disease-free survival (DFS), disease-free survival, From date of randomization until the date of recurrence, assessed up to 60 months
recurrence rate, recurrence rate, 1 year, 2 year, 3 year, 5 year after surgery|Overall survival (OS), overall survival, From date of randomization until the date of death from any cause, assessed up to 60 months
To compare The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.